1. Abrey LE, Batchelor TT, Ferreri AJ, et al.; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–43.
2. Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 2003;21:1044–9.
3. Berghoff AS, Ricken G, Widhalm G, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 2014;33:42–9.
4. Birnbaum T, Stadler EA, von Baumgarten L, et al. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 2012;109:285–91.
5. Borsi JD, Moe PJ. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer 1987;60:5–13.
6. CBTRUS. Primary brain and central nervous system tumors diagnosed in the United States 2007–2011. Neuro Oncol 2012;16(Suppl 4).
7. Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012;14:101–8.
8. Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011;25:1797–807.
9. Doolittle ND, Korfel A, Lubow M, et al. Long-term cognitive function, neuroimaging and quality of life in primary CNS lymphoma. Neurology 2013;81:84–92.
10. Enting RH, Demopoulos A, De Angelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901–3.
11. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–20.
12. Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006;17:1141–5.
13. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16:1561–7.
14. Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol 2013;15:1068–73.
15. Herrlinger U, Brugger W, Bamberger M, et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000;54:1707–8.
16. Herrlinger U, Küker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843–7.
17. Herrlinger U, Glantz M, Schlegel U, et al. Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more. Semin Oncol 2009;36:25–34.
18. Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015;16:e322–32.
19. Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS. Neurology 2014;84:325–6.
20. Illerhaus G, Fritsch K, Egerer G, et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma – a multicentre study by the Collaborative PCNSL Study Group Freiburg. ASH Meeting 8.–11.12.2012, Atlanta, Abstract 302.
21. Illerhaus G, Marks R, Ihorst G, et al. High dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–70.
22. Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005;16:445–9.
23. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67:182–9.
24. Kasenda B, Schorb E, Fritsch K, et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma – a long-term follow-up study. Ann Oncol 2012;23:2670–5.
25. Kiewe P, Martus P, Thiel E, et al. Phase II trial of temsirolimus for relapsed/refractory primary central nervous system lymphoma (PCNSL). Oncol Res Treat 2014;37(Suppl 5):268.
26. Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 2013;9:317–27.
27. Korfel A, Schlegel U. Primary ZNS lymphoma – progress in the diagnostics and therapy. Nervenarzt 2015;86:710–5.
28. Korfel A, Weller M, Martus P, et al. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNL): Experience from the G-PCNSL-SG1 trial. Ann Oncol 2012;23:2374–80.
29. Küker W, Nägele T, Thiel E, et al. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology 2005;65:1129–31.
30. Li Z, Qiu Y, Personett D, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One 2013;8:e71754.
31. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393–402.
32. Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010;116:4605–12.
33. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005;62:1595–600.
34. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489–95.
35. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with highdose methotrexate. Clin Cancer Res 2004;10:5643–6.
36. Ponzoni M, Issa S, Batchelor TT, et al. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 2014;25:316–22.
37. Porter AB, Giannini C, Kaufmann T, et al. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol 2008;63:662–7.
38. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007;96:864–7.
39. Roth P, Martus P, Kiewe P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012;79:890–6.
40. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–8.
41. Rubenstein J, His E, Johnson J, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31:3061–8.
42. Szabatura AH, Cirrone F, Harris C, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 2015;21:188–93.
43. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–47.
44. Weller M, Martus P, Roth P, et al.; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012;14:1481–4.
Prof. Dr. med. Uwe Schlegel, Neurologische Universitätsklinik, Knappschaftskrankenhaus, Klinikum der Ruhruniversität, In der Schornau 23–25, 44892 Bochum, E-Mail: email@example.com
Priv.-Doz. Dr. med. Agnieszka Korfel, Klinik für Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12200 Berlin